Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer marketed by Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) ...

All 3 strengths of iron sucrose injection are expected to be available “imminently”. The Food and Drug Administration (FDA) has approved the first generic version of Venofer ® (iron sucrose) Injection ...

Amphastar has received permission from the Food and Drug Administration for iron sucrose injection, 50mg/2.5ml, 100mg/5ml and 200mg/10ml in single-dose vials, previously referred to as AMP-002. Iron ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...

Generic versions of CSL’s iron replacement therapy Venofer have arrived in the U.S. after a yearslong wait. Monday, Viatris and Amphastar Pharmaceuticals both said they have received the FDA’s ...

(RTTNews) - Viatris (VTRS) announced the FDA has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia in adult and pediatric patients with ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan ...